Is routine ultrasound guidance really necessary for closure of patent foramen ovale using the Amplatzer PFO occluder?
- PMID: 19133676
- DOI: 10.1002/ccd.21859
Is routine ultrasound guidance really necessary for closure of patent foramen ovale using the Amplatzer PFO occluder?
Abstract
Objectives: The aim of the study was to evaluate safety, efficacy, and long-term clinical outcome of percutaneous closure of patent foramen ovale (PFO closure) in a low volume center using the Amplatzer PFO occluder without echocardiographic guidance.
Background: Most centers perform PFO closure either by transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE) guidance for optimal device selection. As TEE is poorly tolerated by patients in supine position and ICE is a costly alternative that increases vascular access complications, we wanted to assess the safety and efficacy of PFO closure by fluoroscopic guidance only.
Methods: Before PFO closure, all patients had a diagnostic contrast-TEE and morphological classification of PFO. All PFO closures were performed using the 25-mm Amplatzer PFO occluder with fluoroscopic guidance only. Intraprocedural echocardiography was replaced by right atrial opacification using contrast angiography. Contrast TEE was done after 6 weeks, contrast TTE after 3, 6, and 12 months postprocedural.
Results: In all 92 patients (52.4 +/- 1.5 years), a 25-mm Amplatzer PFO occluder was implanted in the correct position. Total fluoroscopic time was 8.4 +/- 0.6 minutes and the application of contrast medium was 122.5 +/- 5.8 mL. By contrast-TEE, 12 patients (13 %) showed a small residual shunt (grade 1). During follow-up (2.09 +/- 0.13 years) two patients (2.1%) suffered from a recurrent event (TIA in both cases).
Conclusions: Percutaneous closure of PFO using the 25-mm Amplatzer PFO occluder guided by fluoroscopy only is a safe and efficacious intervention for nearly all patients.
Copyright 2009 Wiley-Liss, Inc.
Comment in
-
What is the best way to close a PFO?Catheter Cardiovasc Interv. 2009 Feb 15;73(3):367. doi: 10.1002/ccd.21987. Catheter Cardiovasc Interv. 2009. PMID: 19213090 No abstract available.
Similar articles
-
Percutaneous patent foramen ovale closure using Helex and Amplatzer devices without intraprocedural echocardiographic guidance.J Interv Cardiol. 2011 Jun;24(3):271-7. doi: 10.1111/j.1540-8183.2010.00612.x. Epub 2010 Nov 28. J Interv Cardiol. 2011. PMID: 21114532
-
Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size.JACC Cardiovasc Interv. 2009 Feb;2(2):116-23. doi: 10.1016/j.jcin.2008.09.013. JACC Cardiovasc Interv. 2009. PMID: 19463412
-
Safety and feasibility of day case patent foramen ovale (PFO) closure facilitated by intracardiac echocardiography.Int J Cardiol. 2009 Jan 24;131(3):438-40. doi: 10.1016/j.ijcard.2007.07.141. Epub 2007 Nov 26. Int J Cardiol. 2009. PMID: 18037512
-
Practical Aspects of Patent Foramen Ovale Closure: Ultrasound and Fluoroscopic Guidance.Cardiol Clin. 2024 Nov;42(4):537-545. doi: 10.1016/j.ccl.2024.02.001. Epub 2024 Mar 13. Cardiol Clin. 2024. PMID: 39322344 Review.
-
Advances in Percutaneous Patent Foramen Ovale Closure: From the Procedure to the Echocardiographic Guidance.J Clin Med. 2022 Jul 11;11(14):4001. doi: 10.3390/jcm11144001. J Clin Med. 2022. PMID: 35887765 Free PMC article. Review.
Cited by
-
Safety and Efficacy of the Amplatzer Septal Occluder: A Systematic Review and Meta-Analysis.Cardiovasc Revasc Med. 2022 Apr;37:52-60. doi: 10.1016/j.carrev.2021.06.002. Epub 2021 Jun 17. Cardiovasc Revasc Med. 2022. PMID: 34183276 Free PMC article.
-
Percutaneous closure of simple congenital heart diseases under echocardiographic guidance.Eur J Med Res. 2023 Oct 7;28(1):408. doi: 10.1186/s40001-023-01398-8. Eur J Med Res. 2023. PMID: 37805534 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials